Fabrizia Urbinati

Dr. Fabrizia Urbinati earned her PhD in Biotechnology and Genetic Medicine at the University of Modena and Reggio Emilia (Italy), where she gained her initial experience in gene therapy for hematopoietic diseases. Dr. Urbinati furthered her expertise in gene therapy for hemoglobinopathies at the Children’s Hospital of Los Angeles and Cincinnati Children’s Hospital. Her commitment to translational medicine led her to the University of California, Los Angeles, where she focused on bringing a gene therapy clinical trial for sickle cell disease patients from bench to the bedside. Driven by her aspiration to explore the advanced stages of gene and cell therapy beyond academia, Dr. Urbinati transitioned into the industry. She initiated her industry journey at PACT Pharma, where she contributed to the advancement of process development for an innovative T-cell therapy targeting solid tumors. More recently, she assumed a leadership role within the early discovery team at Astellas Gene Therapy (formerly Audentes), leading the development of AAV gene therapy products for neuromuscular disorders. Dr. Urbinati is dedicated to translating gene and cell therapy research into valuable cures for patients, with a profound passion for the transformative potential of these therapies.